Propofol attenuates BV2 microglia inflammation via NMDA receptor inhibition

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Canadian Journal of Physiology and Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>cjpp-2017-0243.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>09-Jun-2017</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Wu, Qichao; Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. Zhao, Yanjun; Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai, China. Chen, Xiangyuan; Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. Zhu, Minmin; Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai, China. Miao, Changhong; Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai, China.</td>
</tr>
<tr>
<td>Is the invited manuscript for consideration in a Special Issue?:</td>
<td>N/A</td>
</tr>
<tr>
<td>Keyword:</td>
<td>Propofol, BV2, LPS, CaMK II</td>
</tr>
</tbody>
</table>
Propofol attenuates BV2 microglia inflammation via NMDA receptor inhibition

Qichao Wu1, 2#, Yanjun Zhao1#, Xiangyuan Chen1, 2#, Minmin Zhu1*, Changhong Miao1*

1 Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Shanghai, P.R. China.
2 Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai, China.
* Corresponding Author
# equal contributes

Running Title: Propofol attenuates BV2 inflammation

Corresponding author:
Minmin Zhu, Ph.D., Changhong Miao, Ph.D.
Fudan University Shanghai Cancer Center
Department of Anaesthesiology
No.270 DongAn Road, Shanghai, 200032, P.R.China.
Phone: 86-21-64175590
E-mail address: zhu_mm@126.com
E-mail address: miao_chh@126.com
ABSTRACT

Activated microglia, involved in the occurrence and improvement of sepsis-associated encephalopathy, can induce the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, resulting in inflammation-mediated neuronal cell death. It was reported that propofol could inhibit lipopolysaccharide (LPS)-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression in BV2 and primary microglial cells. However, the underlying mechanism is not well known. In the present study, we investigated whether and how propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2 cells. LPS induced pro-inflammatory cytokines and pro-inflammatory enzymes expression, NF-κB, extracellular regulated kinase 1/2 (ERK) and Calcium (Ca\(^{2+}\))/calmodulin-dependent protein kinase II (CaMK II) phosphorylation, and BV2 cells Ca\(^{2+}\) accumulation. Propofol could reverse these effects induced by LPS. MK801, an inhibitor of NMDA receptor, could attenuate LPS-induced Ca\(^{2+}\) accumulation, the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, phosphorylation of NF-κB, ERK and CaMK II, which was similar with propofol. Moreover, these effects of propofol could be counteracted by rapastinel, an activator of NMDA receptor. The present study suggested that propofol, via inhibiting NMDA receptor, attenuating Ca\(^{2+}\)
accumulation, inhibiting CaMK II, ERK1/2 and NF-κB phosphorylation, down-regulated LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression.

**Key words:** Propofol, BV2, LPS, CaMK II.
INTRODUCTION

Sepsis-associated encephalopathy acts as brain dysfunction induced by a systemic inflammation without a direct brain infection in critically ill patients (Girard et al. 2010; Gofton and Young 2012; Iwashyna et al. 2012), and it is a common syndrome, which is associated with an increased rate of morbidity and mortality in sepsis patients. It is reported that microglia activation is involved in the occurrence and progression of sepsis-associated encephalopathy (Michels et al. 2015). Activated microglia can induce the expression of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) (Michels et al. 2015), and pro-inflammatory enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase II (COX II) (Fu et al. 2014), resulting in inflammation-mediated neuronal cell death. Studies have indicated that extracellular regulated kinase 1/2 (ERK1/2) and NF-κB activation plays an important role in pro-inflammatory enzymes and cytokines expression in LPS-treated BV2 cells (a microglia cell line) (Liu et al. 2014; Matsuda et al. 2003; Sakon et al. 2003).

The intravenous general anesthetic propofol is frequently employed for the sedation of critically ill patients. Previous studies indicated that propofol could inhibited lipopolysaccharide (LPS)-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2 and primary microglial cells (Luo et al. 2013; Peng et al. 2014). However,
the underlying mechanisms by which propofol inhibited LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression have not been well studied. In the present study, we investigated whether and how propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2 cells.
MATERIALS AND METHODS

Cell culture and reagent

BV2 cells were cultured in DMEM and 10% fetal bovine serum in incubator containing 5% CO₂ at 37 °C. Cells were sub-cultured when reaching 90% confluence.

KN93 (an inhibitor of CaMK II), MK801 (an inhibitor of NMDA receptor) and rapastinel (an activator of NMDA receptor), were purchased from Sigma (St. Louis, MO)

Study design

Cells were cultured with 1µg/ml LPS for 6h. At the end of 4h incubation, cells were co-incubated with different concentrations (5, 25, 50 and 100µM) of propofol for the last 2h. The optimal concentration of propofol with significant inhibitory effects on pro-inflammatory cytokines and pro-inflammatory enzymes expression was determined. These treatment conditions were used in the following studies in which cells were cultured and divided into six groups to examine the underlying signaling pathways. Group 1: cells were cultured in DMEM as control; Group 2: cells were treated with 1µg/ml LPS for 6h; Group 3: cells were treated with LPS for 4h, followed by co-incubation with 50µM propofol for the last 2h; Group 4: cells were treated with LPS for 4h, followed by
co-incubation with 10μM KN93 for the last 2h; Group 5: cells were treated with LPS for 4h, followed by co-incubation with 25μM MK801 for the last 2h; Group 6: cells were treated with LPS for 4h, followed by co-incubation with 50μM propofol and 10μM rapastinel for the last 2h.

**Real-time quantitative RT-PCR**

Total RNA extracts were prepared with the use of trizol (Invitrogen). mRNA was reverse transcribed using the PrimeScript™ RT reagent Kit (TaKaRa). Real-time PCR was performed using the Applied Biosystems HT7900 PCR system with 2×QuantiFast SYBR Green PCR Master Mix (Qiagen), 0.2 μmol/L primers, and <1 μg cDNA in a 10μL reaction mixture. The oligonucleotide primers for β-actin were CTGTCCCTGTATGCCTCTG (forward) and ATGTACGCACGATTTCC (reverse); for COXII were TGAGTACCGCAACGCTTCTC (forward) and TGGACGAGGTTTTTCCCACCCAG (reverse); for iNOS were CAGCTGGGCTGTACAAACCTT (forward) and CATTTGAAGTCGTTTCCACAG (reverse); for IL-1β were GAAATGCCACCTTTTGACAGTG (forward) and CATTGGAATGTGAAGCCTTCG (reverse); for IL-6 were CCAATGCTCTCCTAACCAGAT (forward) and TGTCCACAAAACGTATGCT (reverse); for IL-1α were
ACGTCAGCAACGGGAAGAT (forward) and AAGGTGCTGATCTGGGTTGG (reverse); for TNF-α were ACTCTGACCCCTTTACTCTG (forward) and GAGCCATAATCCCTTTCTTA (reverse). The data were expressed as fold increase compared with control group.

**Western Blot Analysis**

Protein extracts were prepared with the use of cell lysis buffer (Cell Signaling Technology, Danvers, MA). Equal amount of protein extracted from different groups of cells was separated by 8 or 10 % SDS-PAGE and transferred to PVDF membranes. After being blocked in 5 % skim milk, the membranes were incubated with correspondent primary antibody at 4 °C for overnight. The primary antibodies used were monoclonal antibody against β-actin (catalog sc-70319, Santa Cruz Biotechnology, Santa Cruz, CA), NMDA receptors GluN2B subunit (NMDA R2B) (catalog 4207, Cell Signaling Technology, Danvers, MA), p-ERK1/2 (catalog sc-81492, Santa Cruz Biotechnology, Santa Cruz, CA), ERK1/2 (catalog 4695, Cell Signaling Technology, Danvers, MA), Calcium (Ca²⁺)/calmodulin-dependent protein kinase II (CaMK II) (catalog ab195518, Abcam, Cambridge, UK), p-CaMK II (catalog 12716, Cell Signaling Technology, Danvers, MA), NF-κB (catalog 4764, Cell Signaling Technology, Danvers, MA), p-NF-κB (catalog 3033, Cell Signaling Technology, Danvers, MA), and others.
Signaling Technology, Danvers, MA). Thereafter, the primary antibodies were washed away, and the membranes were incubated with secondary antibodies for 1 h at room temperature. Subsequently, the membranes were washed and detected by the ECL system. The respective densities of the protein bands were analyzed by UN SCAN-IT gel software. In the present study, β-actin was used as loading control in protein extracts.

**Ca^{2+} concentration assay**

Cells Ca^{2+} concentration was detected by the Calcium Detection Kit (Abcam, Cambridge, UK) according to the datasheet. Briefly, after being washed by cold PBS, cells were re-suspended in 500 µL of Calcium Assay Buffer and homogenized quickly by pipetting up and down a few times. The supernatant were collected by centrifuge and transferred to a clean tube. After adding 90 µL of the Chromogenic Reagent and 60 µL of Calcium Assay Buffer into each well, the mixture was incubate at room temperature for 5-10 minutes protected from light. The absorbance was read at 575 nm spectrophotometrically and the data was expressed as the percentage of the control group.

**Statistical Analysis**

Data were obtained from 5 separately performed experiments and are expressed as mean±SD. N represents the times of repeated
experiments using different cell cultures.

Statistical comparison was performed with one-way analysis of variance followed with Bonferroni-corrected pairwise comparisons using GraphPad Prism 5.0 software (San Diego, CA, USA). A post hoc value of \( P < 0.05 \) was considered significant.
RESULTS

Propofol inhibits LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression.

In BV2 cells, compared with control group, LPS caused a marked increase of COX II, iNOS, IL-1α, IL-1β, IL-6 and TNF-α expression (Figure 1, p<0.05). We also found that propofol could attenuate LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in a concentration-dependent manner. Incubation of cells with 50µM propofol for 2 hours caused a significant inhibition of LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression (Figure 1, p<0.05 compared with LPS treatment).

Propofol inhibits LPS-induced phosphorylation of NF-κB and ERK1/2.

Compared with control group, LPS up-regulated NF-κB and ERK1/2 phosphorylation (Figure 2, p<0.05). Moreover, propofol could attenuate these effects of LPS in a concentration-dependent manner. Incubation of cells with 50µM propofol for 2 hours caused a significant inhibition of LPS-induced NF-κB and ERK1/2 phosphorylation (Figure 2, p<0.05 compared with LPS treatment).

Propofol inhibits LPS-induced phosphorylation of CaMK II and Ca^{2+} accumulation.
Compared with control group, LPS up-regulated CaMK II phosphorylation (Figure 3A-B, p<0.05) and increased Ca$^{2+}$ concentration (Figure 3C, p<0.05). Moreover, propofol could reverse these effects of LPS in a concentration-dependent manner. Incubation of cells with 50µM propofol for 2 hours caused a significant inhibition of LPS-induced CaMK II phosphorylation (Figure 3A-B, p<0.05 compared with LPS treatment) and Ca$^{2+}$ accumulation (Figure 3C, p<0.05 compared with LPS treatment).

This treatment condition of propofol was used in the following experiments to explore the signaling pathways responsible for the protective effects of propofol.

*LPS-mediated CaMK II phosphorylation and Ca$^{2+}$ accumulation, and its modulation by propofol, KN93, MK801 and rapastinel.*

The expression of NMDA R2B was not effected by Propofol, KN93, MK801 and rapastinel (Figure 4A-B).

KN93, an inhibitor of CaMK II, attenuated LPS-induced CaMK II phosphorylation (Figure 4A, C, p<0.05 compared with LPS treatment), which was similar with propofol. However, KN93 did not affect LPS-mediated Ca$^{2+}$ accumulation (Figure 4D).

MK801, an inhibitor of NMDA receptor, attenuated LPS-induced CaMK II phosphorylation (Figure 4A, C, p<0.05 compared with LPS treatment) and Ca$^{2+}$ accumulation (Figure 4D, p<0.05 compared with LPS treatment).
treatment), which was similar with propofol. Moreover, the effects of propofol could be reversed by rapastinel, an activator of NMDA receptor (Figure 4A, C, D).

**LPS-mediated ERK1/2 and NF-κB phosphorylation, and its Modulation by propofol, KN93, MK801 and rapastinel.**

KN93 and MK801 inhibited LPS-induced ERK1/2 and NF-κB phosphorylation (Figure 5A-C, p<0.05 compared with LPS treatment), which was similar with propofol. Moreover, the effects of propofol could be counteracted by rapastinel (Figure 5A-C).

**LPS-mediated pro-inflammatory cytokines and pro-inflammatory enzymes expression, and its modulation by Propofol, KN93, MK801 and rapastinel.**

KN93 and MK801 inhibited LPS-mediated the expression of pro-inflammatory cytokines and pro-inflammatory enzymes (Figure 6, p<0.05 compared with LPS treatment), which was similar with propofol. Moreover, the effects of propofol could be inhibited by rapastinel (Figure 6).
DISCUSSION

In the present study, we found that propofol could inhibit LPS-induced BV2 cells inflammation via attenuating LPS-mediated expression of pro-inflammatory cytokines and pro-inflammatory enzymes. Our data also suggested that the protective effects of propofol might be achieved by inhibiting NMDA receptor, inhibiting LPS-mediated Ca$^{2+}$ accumulation, and attenuating LPS-induced phosphorylation of CaMK II, ERK1/2 and NF-κB.

Previous studies indicated that ERK1/2 and NF-κB activation plays an important role in the LPS-induced expressions of pro-inflammatory enzymes and pro-inflammatory cytokines in microglia and BV2 cells (Liu et al. 2014; Matsuda et al. 2003; Sakon et al. 2003). These results were quite similar with ours. In the present study we found LPS up-regulated CaMK II phosphorylation. Moreover, KN93, a CaMK II inhibitor, could inhibit LPS-induced ERK1/2 and NF-κB phosphorylation. These data suggested that CaMK II is the upstream of ERK1/2 and NF-κB in LPS-induced BV2 cells activation. Ca$^{2+}$ could regulate the activities of CaMKs which are multifunctional serine/threonine kinases (Hook and Means 2001). Previous studies indicated that LPS increased Ca$^{2+}$ accumulation in BV2 cells (Yuan et al. 2016). In the present study, we also found LPS could increase BV2 cells Ca$^{2+}$ concentration, which may in turn up-regulate CaMK II phosphorylation, thus inducing ERK1/2 and
NF-κB phosphorylation, leading to BV2 cells activation.

Propofol is an intravenous anesthetic agent which is widely used for the sedation of critically ill patients. Previous studies indicated that propofol inhibited LPS-induced pro-inflammatory enzymes and pro-inflammatory cytokines expression in BV2 cells (Luo et al. 2013; Peng et al. 2014), which was similar with the present study. However, the neuro-protective function of propofol was not well recognized. Propofol exerts its effects by activating GABA<sub>A</sub> receptor (Mohammadi et al. 2001; Reiner et al. 2013) and inhibiting NMDA receptor (Irifune et al. 2003) in central nervous system (CNS). Previous study indicated that GABA<sub>A</sub> receptor agonist bicuculline or picrotoxin did not reverse the inhibition effect of propofol on LPS-mediated BV2 cells activation (Luo et al. 2013; Peng et al. 2014). These data was quite similar with our pre-experiments (data not shown). So we further explored whether NMDA receptor participated in the protective effect of propofol. NMDA receptors widely exist in CNS (Shibuta et al. 2001; Trapani et al. 2000). In the present study NMDA receptor was also found to be expressed in the BV2 cells (Figure 4A). NMDA R2B has been found to exhibit a main channel function in brain (Carroll and Zukin 2002; Sobczyk et al. 2005). Activation of NMDA receptors containing GluN2B subunit causes Ca<sup>2+</sup> influx (Carroll and Zukin 2002), thus increasing intracellular Ca<sup>2+</sup> concentration. Ca<sup>2+</sup> could regulate the activities of CaMKs which are
multifunctional serine/threonine kinases (Hook and Means 2001). Propofol was reported to inhibit NMDA subtype of glutamate receptor via an allosteric modulation of channel gating, thus decreased the probability of channel opening (Orser et al. 1995). In the present study, the expression of NMDA R2B was not affected by propofol, however we found propofol inhibited LPS-induced Ca$^{2+}$ accumulation and CaMK II phosphorylation, thus attenuating LPS-mediated BV2 cells activation. Our study also indicated that the protective effect of propofol is similar with MK801, an inhibitor of NMDA receptor. Moreover, the protective effects of propofol could be reversed by rapastinel, an activator of NMDA receptor. These results strongly indicated that the protective effects of propofol on LPS-mediated BV2 cells inflammation was achieved by inhibition of NMDA receptor.

In the present study, 50µM Propofol was found to attenuate LPS-induced BV2 cells inflammation. In patients, the brain concentrations of propofol during anesthesia ranged from 11 to 33µM (Ellerkmann et al. 2004; Iannuzzi et al. 2005; Kreuer et al. 2004), and high concentrations of propofol could be more damaging than beneficial. However, it was reported that in murine the concentration of propofol in whole brain during anesthesia is about 75µM (Shyr et al. 1995). In the present study, we used BV2, which is a murine microglia cell line. Therefore, in this study, 50µM propofol was considered to be an
appreciate concentration of propofol to study the protective effect of propofol against LPS-induced inflammation in BV2 cells. However, the present study needs to be further confirmed by *in vivo* study.

The present study has some limitations. First, the study was carried out in BV2 cells, which is an *in vitro* system. It differs from *in vivo* settings, especially considering effectiveness and toxicity of medicine. Second, BV2-HT22 neuronal co-culture was not used to evaluate the effects of propofol on inflammation-induced neuronal death. Further studies using BV2-HT22 neuronal co-culture are necessary to clarify these issues.

In summary, the present study suggested that LPS, by inducing Ca\(^{2+}\) accumulation, CaMK II, ERK1/2 and NF-κB phosphorylation, up-regulated the expression of pro-inflammatory cytokines and pro-inflammatory enzymes. Importantly, our study demonstrated that propofol, via inhibiting NMDA receptor, attenuating Ca\(^{2+}\) accumulation, inhibiting CaMK II, ERK1/2 and NF-κB phosphorylation, down-regulated LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes. Our data implied the potential advantage of the administration of propofol to provide sedation and cerebral protection in sepsis patients in intensive care unit.
ACKNOWLEDGMENTS

Funding: This work was supported by the national natural science foundation of China (No. NSFC1313).

The co-authors have read the manuscript and approved its submission to Canadian journal of physiology and pharmacology.

CONFLICT OF INTEREST

None.
REFERENCES


LEGEND TO FIGURES

Figure 1. Propofol inhibits LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A-F) Propofol attenuated LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in a concentration-dependent manner. Incubation of cells with 50µM propofol for 2 hours caused a significant inhibition of LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression. Propofol solvent dimethyl sulfoxide (DMSO) did not affect LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)

Figure 2. Propofol inhibits LPS-induced phosphorylation of NF-κB and ERK1/2. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-NF-κB, NF-κB, p-ERK1/2 and ERK1/2. (B) The protein expression ratio of p-NF-κB and NF-κB. The ratio in the control group was set as 1. (C) The protein
expression ratio of p-ERK1/2 and ERK1/2. The ratio in the control group was set as 1. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)

Figure 3. Propofol inhibits LPS-induced phosphorylation of CaMK II and Ca\(^{2+}\) accumulation. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-CaMK II and CaMK II. (B) The protein expression ratio of p-CaMK II and CaMK II. The ratio in the control group was set as 1. (C) propofol inhibited LPS-mediated Ca\(^{2+}\) accumulation in a concentration-depend manner. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)

Figure 4. LPS-mediated CaMK II phosphorylation and Ca\(^{2+}\) accumulation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus repastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to NMDA R2B, CaMK II and p-CaMK II. (B) The protein expression ratio of NMDA R2B and
β-actin. The ratio in the control group was set as 1. (C) The protein expression ratio of p-CaMK II and CaMK II. The ratio in the control group was set as 1. (D) Propofol inhibited LPS-mediated Ca\(^{2+}\) accumulation, which was similar to MK801. Moreover, the effect of propofol could be counteracted by rapastinel. KN93 had no effect on cells Ca\(^{2+}\) concentration. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)

**Figure 5.** LPS-mediated ERK1/2 and NF-κB phosphorylation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus rapastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-NF-κB, NF-κB, p-ERK1/2 and ERK1/2. (B) The protein expression ratio of p-NF-κB and NF-κB. The ratio in the control group was set as 1. (C) The protein expression ratio of p-ERK1/2 and ERK1/2. The ratio in the control group was set as 1. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)

**Figure 6.** LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression, and its modulation by
propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus rapastinel for the last 2h. (A-F) Propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, which was similar to KN93 and MK801. Moreover, the effect of propofol could be counteracted by rapastinel. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)
Figure 1. Propofol inhibits LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A-F) Propofol attenuated LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in a concentration-dependent manner. Incubation of cells with 50µM propofol for 2 hours caused a significant inhibition of LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression. Propofol solvent dimethyl sulfoxide (DMSO) did not affect LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)
Figure 2. Propofol inhibits LPS-induced phosphorylation of NF-κB and ERK1/2. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-NF-κB, p-ERK1/2 and ERK1/2. (B) The protein expression ratio of p-NF-κB and β-actin. The ratio in the control group was set as 1. (C) The protein expression ratio of p-ERK1/2 and ERK1/2. The ratio in the control group was set as 1. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)
Figure 3. Propofol inhibits LPS-induced phosphorylation of CaMK II and Ca2+ accumulation. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with different concentration (5, 25, 50, 100µM) of propofol for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-CaMK II and CaMK II. (B) The protein expression ratio of p-CaMK II and CaMK II. The ratio in the control group was set as 1. (C) propofol inhibited LPS-mediated Ca2+ accumulation in a concentration-depend manner. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, n = 5. Data are shown as mean ± SD.)

209x250mm (300 x 300 DPI)
Figure 4. LPS-mediated CaMK II phosphorylation and Ca2+ accumulation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus rapastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to NMDA R2B, CaMK II and p-CaMK II. (B) The protein expression ratio of NMDA R2B and β-actin. The ratio in the control group was set as 1. (C) The protein expression ratio of p-CaMK II and CaMK II. The ratio in the control group was set as 1. (D) Propofol inhibited LPS-mediated Ca2+ accumulation, which was similar to MK801. Moreover, the effect of propofol could be counteracted by rapastinel. KN93 had no effect on cells Ca2+ concentration. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)
Figure 5. LPS-mediated ERK1/2 and NF-κB phosphorylation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus rapastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-NF-κB, p-ERK1/2 and ERK1/2. (B) The protein expression ratio of p-NF-κB and β-actin. The ratio in the control group was set as 1. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)

209x250mm (300 x 300 DPI)
Figure 6. LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus rapastinel for the last 2h. (A-F) Propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, which was similar to KN93 and MK801. Moreover, the effect of propofol could be counteracted by rapastinel. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, &P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.)

209x250mm (300 x 300 DPI)